Benchmark Starts Exact Sciences (EXAS) at Buy; Data Suggest Cologuard Can Clear the Efficacy Hurdle
Tweet Send to a Friend
Benchmark initiates coverage on Exact Sciences (NASDAQ: EXAS) with a Buy. PT $9.
Benchmark analyst says, "We believe EXAS shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Benchmark analyst says, "We believe EXAS shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
